Follow
Joseph Montecalvo
Joseph Montecalvo
Senior Staff Pathologist at Henry Ford Health System
Verified email at hfhs.org
Title
Cited by
Cited by
Year
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
A Drilon, N Rekhtman, M Arcila, L Wang, A Ni, M Albano, ...
The Lancet Oncology 17 (12), 1653-1660, 2016
4202016
SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization
MK Baine, MS Hsieh, WV Lai, JV Egger, AA Jungbluth, Y Daneshbod, ...
Journal of Thoracic Oncology 15 (12), 1823-1835, 2020
2862020
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
JK Sabari, GC Leonardi, CA Shu, R Umeton, J Montecalvo, A Ni, R Chen, ...
Annals of Oncology 29 (10), 2085-2091, 2018
2702018
SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas
N Rekhtman, J Montecalvo, JC Chang, D Alex, RN Ptashkin, N Ai, ...
Journal of Thoracic Oncology 15 (2), 231-247, 2020
2232020
Lobectomy is associated with better outcomes than sublobar resection in spread through air spaces (STAS)-positive T1 lung adenocarcinoma: a propensity score–matched analysis
T Eguchi, K Kameda, S Lu, MJ Bott, KS Tan, J Montecalvo, JC Chang, ...
Journal of thoracic oncology 14 (1), 87-98, 2019
1852019
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
A Drilon, R Somwar, BP Mangatt, H Edgren, P Desmeules, A Ruusulehto, ...
Cancer discovery 8 (6), 686-695, 2018
1802018
The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer
AJ Schoenfeld, C Bandlamudi, JA Lavery, J Montecalvo, A Namakydoust, ...
Clinical Cancer Research 26 (21), 5701-5708, 2020
1682020
Immunophenotype and response to immunotherapy of RET-rearranged lung cancers
M Offin, R Guo, SL Wu, J Sabari, JD Land, A Ni, J Montecalvo, ...
JCO precision oncology 3, 2019
1262019
Bronchiolar adenoma: expansion of the concept of ciliated muconodular papillary tumors with proposal for revised terminology based on morphologic, immunophenotypic, and genomic …
JC Chang, J Montecalvo, L Borsu, S Lu, BT Larsen, WD Wallace, ...
The American journal of surgical pathology 42 (8), 1010-1026, 2018
1102018
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices
N Rekhtman, P Desmeules, AM Litvak, MC Pietanza, ML Santos-Zabala, ...
Modern pathology 32 (8), 1106-1122, 2019
682019
Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations
N Rekhtman, CM Pietanza, J Sabari, J Montecalvo, H Wang, O Habeeb, ...
Modern Pathology 31 (1), 111-121, 2018
602018
Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes
JC Chang, M Offin, C Falcon, D Brown, BR Houck-Loomis, F Meng, ...
Clinical Cancer Research 27 (14), 4066-4076, 2021
562021
Histologic subtype in core lung biopsies of early-stage lung adenocarcinoma is a prognostic factor for treatment response and failure patterns after stereotactic body radiation …
JE Leeman, A Rimner, J Montecalvo, M Hsu, Z Zhang, D von Reibnitz, ...
International Journal of Radiation Oncology* Biology* Physics 97 (1), 138-145, 2017
542017
PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC).
JK Sabari, J Montecalvo, R Chen, JA Dienstag, C Mrad, I Bergagnini, ...
Journal of Clinical Oncology 35 (15_suppl), 8512-8512, 2017
492017
Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: a propensity-matched analysis
WS Brandt, W Yan, J Zhou, KS Tan, J Montecalvo, BJ Park, PS Adusumilli, ...
The Journal of thoracic and cardiovascular surgery 157 (2), 743-753. e3, 2019
372019
What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?
EA Aherne, AJ Plodkowski, J Montecalvo, S Hayan, J Zheng, M Capanu, ...
Lung Cancer 118, 83-89, 2018
342018
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
A Drilon, AJ Schoenfeld, KC Arbour, A Litvak, A Ni, J Montecalvo, ...
Molecular Case Studies 5 (2), a003665, 2019
272019
BRMS1 expression in surgically resected lung adenocarcinoma predicts future metastases and is associated with a poor prognosis
PR Bucciarelli, KS Tan, NP Chudgar, W Brandt, J Montecalvo, T Eguchi, ...
Journal of Thoracic Oncology 13 (1), 73-84, 2018
232018
RET-rearranged lung cancers: Immunophenotype and response to immunotherapy.
JK Sabari, MD Offin, SL Wu, A Ni, D Halpenny, J Montecalvo, D Liu, ...
Journal of Clinical Oncology 36 (15_suppl), 9034-9034, 2018
182018
MA12. 05 Can tumor spread through air spaces (STAS) in lung adenocarcinomas be predicted pre-and intraoperatively?
K Kameda, S Lu, T Eguchi, N Rekhtman, J Chang, J Montecalvo, D Jones, ...
Journal of Thoracic Oncology 12 (1), S411-S412, 2017
172017
The system can't perform the operation now. Try again later.
Articles 1–20